Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.
Hurler disease resulting from a deficiency in alpha-L-iduronidase, which causes an accumulation of dermatan sulfate and heparan sulfate glycosaminoglycans, is characterized by connective tissue and skeletal deformations, cardiomyopathy, cardiac valve defects, and progressive coronary artery stenosis. In this report, we present evidence that accumulation of dermatan sulfate but not heparan sulfate moieties is linked to impaired elastic fiber assembly that, in turn, contributes substantially to the development of the clinical phenotype in Hurler disease. Our data suggest that dermatan sulfate-bearing moieties bind to and cause functional inactivation of the 67-kd elastin-binding protein, a molecular chaperone for tropoelastin, which normally facilitates its secretion and assembly into elastic fibers. We demonstrate that, in contrast to normal skin fibroblasts and cells from Sanfilippo disease, which accumulate heparan sulfate, Hurler fibroblasts show reduced expression of elastin-binding protein and do not assemble elastic fibers, despite an adequate synthesis of tropoelastin and sufficient production of a microfibrillar scaffold of elastic fibers. Because cultured Hurler fibroblasts proliferate more quickly than their normal counterparts and the addition of exogenous insoluble elastin reduces their proliferation, we suggest that cell contacts with insoluble elastin play an important role in controlling their proliferation.
Hinek
A
A
Division of Cardiovascular Research, The Hospital for Sick Children, Toronto, Ontario, Canada. alek.hinek@sickkids.on.ca
Wilson
S E
SE
D000293:Adolescent; D002452:Cell Count / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003331:Coronary Vessels / Q000378:metabolism / Q000473:pathology; D003871:Dermatan Sulfate / Q000096:biosynthesis* / Q000494:pharmacology / Q000652:urine; D004547:Elastic Tissue / Q000378:metabolism*; D004549:Elastin / Q000172:deficiency* / Q000378:metabolism; D005260:Female; D005333:Fetus; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D005353:Fibronectins / Q000096:biosynthesis; D019084:Fluorescent Antibody Technique, Indirect; D006497:Heparan Sulfate / Q000096:biosynthesis / Q000494:pharmacology / Q000652:urine; D006801:Humans; D007223:Infant; D008297:Male; D008943:Mitral Valve / Q000378:metabolism / Q000473:pathology; D008059:Mucopolysaccharidosis I / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D009084:Mucopolysaccharidosis III / Q000378:metabolism / Q000473:pathology / Q000652:urine; D011956:Receptors, Cell Surface / Q000172:deficiency* / Q000378:metabolism; D012867:Skin / Q000166:cytology; D014333:Tropoelastin / Q000096:biosynthesis
D003871:Dermatan Sulfate; D004549:Elastin; D005353:Fibronectins; D006497:Heparan Sulfate; D011956:Receptors, Cell Surface; D014333:Tropoelastin; C054901:elastin-binding proteins